Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:ALPN NASDAQ:LPTX NASDAQ:SCYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.52-5.8%$4.04$1.18▼$5.15$631.28M0.761.45 million shs929,226 shsALPNAlpine Immune Sciences$64.97$64.81$8.33▼$65.00$4.46B0.971.92 million shsN/ALPTXLeap Therapeutics$2.05$0.00▼$0.00$84.95M-0.0640.67 million shs760.56 million shsSCYXSCYNEXIS$0.74-4.0%$0.92$0.57▼$1.31$33.05M1.12366,222 shs435,732 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%-8.32%+13.57%+41.69%+283.05%ALPNAlpine Immune Sciences0.00%0.00%0.00%0.00%0.00%LPTXLeap Therapeutics0.00%0.00%0.00%0.00%+204,999,900.00%SCYXSCYNEXIS0.00%-19.19%-29.52%-1.33%-22.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.52-5.8%$4.04$1.18▼$5.15$631.28M0.761.45 million shs929,226 shsALPNAlpine Immune Sciences$64.97$64.81$8.33▼$65.00$4.46B0.971.92 million shsN/ALPTXLeap Therapeutics$2.05$0.00▼$0.00$84.95M-0.0640.67 million shs760.56 million shsSCYXSCYNEXIS$0.74-4.0%$0.92$0.57▼$1.31$33.05M1.12366,222 shs435,732 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%-8.32%+13.57%+41.69%+283.05%ALPNAlpine Immune Sciences0.00%0.00%0.00%0.00%0.00%LPTXLeap Therapeutics0.00%0.00%0.00%0.00%+204,999,900.00%SCYXSCYNEXIS0.00%-19.19%-29.52%-1.33%-22.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.00Buy$11.29149.68% UpsideALPNAlpine Immune Sciences 0.00N/AN/AN/ALPTXLeap Therapeutics 1.00SellN/AN/ASCYXSCYNEXIS 2.00Hold$3.00305.41% UpsideCurrent Analyst Ratings BreakdownLatest ALPN, SCYX, ACRS, and LPTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026ACRSAclaris Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $11.005/5/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/4/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/29/2026ACRSAclaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $10.004/16/2026ACRSAclaris Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.004/16/2026ACRSAclaris Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.003/31/2026ACRSAclaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$8.003/27/2026ACRSAclaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/19/2026ACRSAclaris Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.00(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$8.37M75.45N/AN/A$1.03 per share4.39ALPNAlpine Immune Sciences$56.52M78.85N/AN/A$4.85 per share13.40LPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/ASCYXSCYNEXIS$20.60M1.60N/AN/A$0.92 per share0.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%N/AALPNAlpine Immune Sciences-$32.18M-$0.64N/AN/AN/A-65.17%-14.86%-11.82%N/ALPTXLeap Therapeutics-$67.56M-$1.22N/AN/AN/AN/A-247.44%-146.51%N/ASCYXSCYNEXIS-$8.61M-$0.48N/AN/AN/A-41.79%-57.16%-39.48%5/21/2026 (Estimated)Latest ALPN, SCYX, ACRS, and LPTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026SCYXSCYNEXIS-$0.10N/AN/AN/A$0.08 millionN/A5/11/2026Q1 2026SCYXSCYNEXIS-$0.10-$0.42-$0.32-$0.42$0.08 millionN/A5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million3/4/2026Q4 2025SCYXSCYNEXIS$0.29$0.25-$0.04$0.25$8.10 million$17.20 million2/26/2026Q4 2025ACRSAclaris Therapeutics-$0.15-$0.1614-$0.0114-$0.16$2.07 million$1.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AALPNAlpine Immune SciencesN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03ALPNAlpine Immune SciencesN/A9.569.56LPTXLeap TherapeuticsN/A1.341.34SCYXSCYNEXISN/A3.947.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%ALPNAlpine Immune Sciences75.17%LPTXLeap Therapeutics30.46%SCYXSCYNEXIS54.37%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.60%ALPNAlpine Immune Sciences42.30%LPTXLeap Therapeutics4.30%SCYXSCYNEXIS4.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million131.84 millionOptionableALPNAlpine Immune Sciences14268.60 million39.58 millionNo DataLPTXLeap Therapeutics4041.44 million39.66 millionN/ASCYXSCYNEXIS6044.66 million42.49 millionOptionableALPN, SCYX, ACRS, and LPTX HeadlinesRecent News About These CompaniesAnalyzing Phio Pharmaceuticals (NASDAQ:PHIO) and SCYNEXIS (NASDAQ:SCYX)May 17 at 3:53 AM | americanbankingnews.comSCYNEXIS (NASDAQ:SCYX) Downgraded to Sell Rating by Wall Street ZenMay 16 at 2:26 AM | americanbankingnews.comSCYNEXIS (SCYX) price target increased by 20.73% to 4.28May 14 at 10:19 PM | msn.comSCYNEXIS (SCYX) Projected to Post Quarterly Earnings on ThursdayMay 14 at 2:25 AM | americanbankingnews.comSCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 11, 2026 | globenewswire.comSCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)May 6, 2026 | globenewswire.comSCYNEXIS Raises $40 Million in Strategic Private PlacementApril 19, 2026 | theglobeandmail.comSCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics TranscriptMarch 31, 2026 | seekingalpha.comSCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney ...March 31, 2026 | markets.businessinsider.comWhy did SCYX stock jump 10% in pre-market today?March 31, 2026 | msn.comPoxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 MillionMarch 31, 2026 | businesswire.comSCYNEXIS Announces $40.0 Million Private PlacementMarch 31, 2026 | globenewswire.comSCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)March 31, 2026 | globenewswire.comSCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal TherapyMarch 12, 2026 | insidermonkey.comScynexis: Q4 Earnings SnapshotMarch 4, 2026 | wiltonbulletin.comWSCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate UpdateMarch 4, 2026 | globenewswire.comSCYNEXIS, Inc. Initiates Phase 1 Trial for Intravenous Antifungal SCY-247 Following FDA DesignationsFebruary 26, 2026 | quiverquant.comQSCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247February 26, 2026 | globenewswire.comCERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of DirectorsFebruary 17, 2026 | globenewswire.comSCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural ...January 28, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALPN, SCYX, ACRS, and LPTX Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$4.52 -0.28 (-5.83%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$4.64 +0.12 (+2.63%) As of 05/15/2026 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Alpine Immune Sciences NASDAQ:ALPNAlpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.Leap Therapeutics NASDAQ:LPTXLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.SCYNEXIS NASDAQ:SCYX$0.74 -0.03 (-4.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.74 +0.00 (+0.41%) As of 05/15/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
